Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Edesa Biotech Covid-19 Drug Candidate Gets Positive Review from Independent Data Group

06/18/2021 | 06:54am EDT

By Adriano Marchese

Edesa Biotech Inc. said Friday that an independent committee has recommended that the company's Covid-19 drug candidate study continue as planned.

The clinical-stage biopharmaceutical company said the Data and Safety Monitoring Board, which monitors patient safety and treatment efficacy data during clinical trials, recommended that enrollment in the trial continue.

The recommendation follows an interim review of the first patient cohort participating in Edesa's Phase 2/3 clinical study for the EB05 drug candidate, a single-dose treatment for more serious cases of Covid-19.

Edesa said it has filed a trial amendment with the Food and Drug Administration to streamline the U.S. protocol and align it with other jurisdictions.

"These planned changes could significantly reduce the number of additional patients enrolled in the study and could put us in the position to demonstrate results sooner," Vice President of Research and Development Blair Gordon said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

06-18-21 0854ET

All news about EDESA BIOTECH, INC.
07/13EDESA BIOTECH : Expands Patient Enrollment of Phase 2b Dermatitis Trial to Canad..
MT
07/13EDESA BIOTECH : Extends Dermatitis Study to Canada
PU
07/13Edesa Biotech, Inc. Extends Dermatitis Study to Canada
CI
06/23Edesa Biotech Adds Rajan Puri to the Newly Established Position of Senior Vic..
CI
06/18Edesa Biotech, Inc. Completes Independent Data and Safety Monitoring Board In..
CI
06/18EDESA BIOTECH : Says Independent Safety Panel Backs Continuation of COVID-19 Stu..
MT
06/18EDESA BIOTECH : Reports Favorable Review of COVID-19 Study
PU
06/18Edesa Biotech Covid-19 Drug Candidate Gets Positive Review from Independent D..
DJ
06/08EDESA BIOTECH : to Attend BIO Digital 2021
PU
06/03Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -15,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,42x
Yield 2021 -
Capitalization 66,1 M 66,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 2,70x
Nbr of Employees 12
Free-Float 71,2%
Chart EDESA BIOTECH, INC.
Duration : Period :
Edesa Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDESA BIOTECH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 4,99 $
Average target price 17,00 $
Spread / Average Target 241%
EPS Revisions
Managers and Directors
Pardeep Nijhawan Chief Executive Officer, Secretary & Director
Michael Brooks President
Kathi Niffenegger Chief Financial Officer
Sean A. MacDonald Chairman
Blair Gordon Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
EDESA BIOTECH, INC.17.41%66
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%68 112
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 232